Kolexia
Turhan Ali
Hématologie
Cabinet libéral
Neuilly-sur-Seine, France
187 Activités
212 Followers

Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Leucémie myéloïde chronique BCR-ABL positive Leucémies Leucémie myéloïde Crise blastique Déficience intellectuelle Tératome Transformation cellulaire néoplasique Tumeurs du cerveau Instabilité des chromosomes

Industries

Novartis
16 collaboration(s)
Dernière en 2023
Abbvie
4 collaboration(s)
Dernière en 2022
Pfizer
1 collaboration(s)
Dernière en 2021
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Reliability and validity of the dynamic risk outcome scales-short version for clients with mild intellectual disabilities or borderline intellectual functioning.
Journal of applied research in intellectual disabilities : JARID   23 février 2024
BIRC-3 mutated monoclonal B lymphocytosis without evolution to chronic lymphocytic leukemia (CLL).
Leukemia & lymphoma   31 janvier 2024
Direct reprogramming of hepatocytes into JAK/Stat-dependent LGR5+ liver cells able to initiate intrahepatic cholangiocarcinoma.
Stem cells (Dayton, Ohio)   23 janvier 2024
Cell specification and functional interactions in the pig blastocyst inferred from single-cell transcriptomics and uterine fluids proteomics.
Genomics   09 janvier 2024
Chimeric antigen-receptor (CAR) engineered natural killer cells in a chronic myeloid leukemia (CML) blast crisis model.
Frontiers in immunology   08 janvier 2024
Modeling RET-Rearranged Non-Small Cell Lung Cancer (NSCLC): Generation of Lung Progenitor Cells (LPCs) from Patient-Derived Induced Pluripotent Stem Cells (iPSCs).
Cells   15 décembre 2023
Psychometric analysis of the Group Climate Inventory-Revised in adults with mild intellectual disability or borderline intellectual functioning in a secure residential facility.
Journal of applied research in intellectual disabilities : JARID   03 décembre 2023
Chimeric Antigen-Receptor (CAR)-Engineered Natural Killer (NK) Cells Targeting Chronic Myeloid Leukemia (CML) Blast Crisis
65th ASH Annual Meeting Abstracts   02 novembre 2023
Comparative Transcriptome Analyses in Mantle Cell Lymphoma (MCL): Evidence of E2F1 As a Major Target in Aggressive Blastoid MCL Model
65th ASH Annual Meeting Abstracts   02 novembre 2023
Single Cell Analysis of Genes Involved in Asymmetric Hematopoietic Stem Cell (HSC) Division in Chronic Myeloid Leukemia (CML) : Evidence of the Regulation of Tetraspanin CD63 during Leukemia Progression
65th ASH Annual Meeting Abstracts   02 novembre 2023